UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K/A
CURRENT REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934.
March 22, 2002
Date of Report (Date of Earliest Event Reported)
Neogenomics, Inc.
(Exact name of registrant as specified in charter)
Commission File Number: 333-72097
Nevada 74-2897368
(State of Incorporation) (I.R.S. Employer I.D. No.)
355 Interstate Boulevard
Sarasota, FL 34240
(Address of Principal Executive Offices)
941/923-1949
(Registrant's Telephone Number, Including Area Code)
Item 1. CHANGES IN CONTROL OF REGISTRANT
None.
Item 2. ACQUISITION OR DISPOSITION OF ASSETS
None
Item 3. BANKRUPTCY OR RECEIVERSHIP
None
Item 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.
On March 18, 2002, the Company engaged Kingery, Crouse & Hohl, P.A., as
its principal independent accountant to audit the Company's financial statements
beginning with its fiscal year ending December 31, 2001. The decision to change
principal accountant was recommended by the Board of Directors. Accordingly, the
engagement of Sprouse & Anderson, LLP, the Company's prior independent accountants
was not renewed, effective March 18, 2002.
During the Company's two most recent fiscal years, and during the period
from January 1, 2002 to March 18, 2002, there was no disagreement with Sprouse &
Anderson, LLP, on any matter of accounting principles or practices, financial
1
statement disclosure, or auditing scope or procedures, which disagreement, if
not solved to their satisfaction would have caused them to make reference in
connection with their opinion to the subject matter of the disagreement.
The audit reports on the financial statements of the Company as of and for
the years ended December 31, 2000 and December 31, 1999 did not contain any
adverse opinion or disclaimer opinion, nor were they qualified or modified as to
uncertainty, audit scope, or accounting principles. However, such reports
contained an explanatory paragraph regarding the uncertainty about the Company's
ability to continue as a going concern.
Item 5. OTHER EVENTS
None
Item 6. RESIGNATION OF REGISTRANT'S DIRECTORS
None
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial statements of businesses acquired.
None
(b) Pro forma financial information.
None
(c) Exhibits:
Letter of Sprouse & Winn, LLP
Item 8. CHANGE IN FISCAL YEAR
None
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Neogenomics, Inc.
By: /s/ Matthew A. Veal
Matthew A. Veal, Chief Financial Officer
March 22, 2002
